Biodesix, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Biodesix, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 21% of its market value (net debt). Lower than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-3.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 57% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$60Sales grew 132% in 3 years; of every extra $100 of sales, $60 became extra profit.
Higher than 73% of Healthcare companies in United States.
Asset Productivity Ratio
+132% / -6%In 3 years sales changed by +132% while total assets changed by -6%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-3,878.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
−21%Debt, after subtracting cash, equals 21% of its market value (net debt).
Lower than 85% of Healthcare companies in United States.
Tangible Assets Ratio
78%Of every $100 the company owns, $78 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 53% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Biodesix, Inc. made a loss over the last year. Biodesix, Inc. owes $0.90 for every $1 it owns. Biodesix, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBiodesix, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
27.62The share price is 27.62 times Biodesix, Inc.'s book value per share, higher than 96% of Healthcare companies in United States.
Market cap
$253 MThe total market value of all of Biodesix, Inc.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$9 MWhat Biodesix, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.87Net worth divided by the number of shares. The share price of $23.94 is 27.6 times this, which is the P/B above.
Return on equity (ROE)
-540.0%Biodesix, Inc. lost 540.0% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
Owes vs Owns
0.90×Biodesix, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneBiodesix, Inc. does not currently pay a dividend.
Revenue growth
+24%Revenue rose 24% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Profit growth
LossBiodesix, Inc. made a loss in each of the last two years.
Profit margin
-39.8%Biodesix, Inc. lost $40 for every $100 of revenue.
Interest cover
Not coveredBiodesix, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtBiodesix, Inc. had $54 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Biodesix, Inc.: $253 M ÷ $9 M (30 Jun 2026) = 27.6.
What is Biodesix, Inc.'s return on equity?
Biodesix, Inc. lost 540.0% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
How much does Biodesix, Inc. owe compared with what it owns?
Biodesix, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does Biodesix, Inc. pay a dividend?
No. Biodesix, Inc. does not currently pay a dividend.
Is Biodesix, Inc.'s revenue growing?
Revenue rose 24% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.